{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:39:30Z","timestamp":1780709970942,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81925035"],"award-info":[{"award-number":["81925035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012492","name":"Youth Innovation Promotion Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.apsb.2022.01.019","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:41:12Z","timestamp":1644525672000},"page":"3187-3194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants"],"prefix":"10.1016","volume":"12","author":[{"given":"Bin","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8915","authenticated-orcid":false,"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.01.019_bib1","unstructured":"Covid-19 coronavirus pandemic. Available at: https:\/\/www.worldometers.info\/coronavirus\/. (Accessed Jan 27, 2022)."},{"key":"10.1016\/j.apsb.2022.01.019_bib2","first-page":"91","article-title":"One year of SARS-CoV-2: how much has the virus changed?","volume":"10","author":"Vilar","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.apsb.2022.01.019_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2022.01.019_bib4","first-page":"100276","article-title":"Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians","volume":"15","author":"Wang","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.apsb.2022.01.019_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.019_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.01.019_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2022.01.019_bib8","article-title":"Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein","author":"Wang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2022.01.019_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2020.10.006","article-title":"Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator","volume":"11","author":"Bian","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.01.019_bib10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.apsb.2021.09.004","article-title":"Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles","volume":"3","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.01.019_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12050","article-title":"Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus","volume":"10","author":"Cocozza","year":"2020","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.apsb.2022.01.019_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2020.09.042","article-title":"Angiotensin-converting enzyme 2-containing small extracellular vesicles and exomeres bind the severe acute respiratory syndrome coronavirus 2 spike protein","volume":"160","author":"Zhang","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2022.01.019_bib13","article-title":"Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID-19 therapy","author":"Xie","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2022.01.019_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-021-00604-5","article-title":"The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.01.019_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12112","article-title":"Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies","volume":"10","author":"Troyer","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.apsb.2022.01.019_bib16","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1111\/jcmm.15607","article-title":"Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19\/SARS-CoV-2","volume":"24","author":"Li","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2022.01.019_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12250-008-2992-1","article-title":"The importance of heparan sulfate in herpesvirus infection","volume":"23","author":"O'Donnell","year":"2008","journal-title":"Virol Sin"},{"key":"10.1016\/j.apsb.2022.01.019_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.scib.2021.01.010","article-title":"Binding of the SARS-CoV-2 spike protein to glycans","volume":"66","author":"Hao","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.apsb.2022.01.019_bib19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.apsb.2022.01.019_bib20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/acscentsci.1c00010","article-title":"Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2","volume":"7","author":"Liu","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2022.01.019_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.01.019_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.019_bib23","doi-asserted-by":"crossref","first-page":"104873","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2022.01.019_bib24","first-page":"261","article-title":"Heparin induced bleeding","volume":"26","author":"Hirsh","year":"1984","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.apsb.2022.01.019_bib25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.01.019_bib26","doi-asserted-by":"crossref","first-page":"649575","DOI":"10.3389\/fmolb.2021.649575","article-title":"Heparan\u00a0sulfate facilitates spike protein-mediated SARS-CoV-2 host\u00a0cell invasion and contributes to increased infection of SARS-CoV-2 G614 mutant and in lung cancer","volume":"8","author":"Yue","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2022.01.019_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2021.07.028","article-title":"Repurpose but also (nano)-reformulate! the potential role of nanomedicine in the battle against SARS-CoV2","volume":"337","author":"Tammam","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.01.019_bib28","first-page":"e84","article-title":"Audio interview: India's covid-19 crisis","volume":"384","author":"Rubin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.019_bib29","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.jaut.2021.102715","article-title":"Evolutionary analysis of the Delta and Delta plus variants of the SARS-CoV-2 viruses","volume":"124","author":"Kannan","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.apsb.2022.01.019_bib30","doi-asserted-by":"crossref","first-page":"121133","DOI":"10.1016\/j.ijpharm.2021.121133","article-title":"Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: a patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion","volume":"609","author":"Ebrahimi","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.01.019_bib31","doi-asserted-by":"crossref","first-page":"121122","DOI":"10.1016\/j.ijpharm.2021.121122","article-title":"Inhaled Edoxaban dry powder inhaler formulations:\u00a0development, characterization and their effects on the coagulopathy\u00a0associated with COVID-19 infection","volume":"608","author":"Rashid","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.01.019_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.immuni.2016.02.026","article-title":"Phagocytosis: an immunobiologic process","volume":"44","author":"Gordon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2022.01.019_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.01.019_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.01.019_bib35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00281-016-0558-0","article-title":"The host immune response in respiratory virus infection: balancing virus clearance and immunopathology","volume":"38","author":"Newton","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.apsb.2022.01.019_bib36","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.matt.2021.04.005","article-title":"Nanotraps for the containment and clearance of SARS-CoV-2","volume":"4","author":"Chen","year":"2021","journal-title":"Matter"},{"key":"10.1016\/j.apsb.2022.01.019_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1183\/09031936.02.00105202","article-title":"Effect of inhaled heparin on lung function and coagulation in healthy volunteers","volume":"19","author":"Bendstrup","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2022.01.019_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jamp.2015.1273","article-title":"Inhaled heparin: therapeutic efficacy and recent formulations","volume":"30","author":"Yildiz-Pekoz","year":"2017","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.apsb.2022.01.019_bib39","doi-asserted-by":"crossref","first-page":"116800","DOI":"10.1016\/j.carbpol.2020.116800","article-title":"A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers","volume":"250","author":"Rasul","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2022.01.019_bib40","doi-asserted-by":"crossref","first-page":"117232","DOI":"10.1016\/j.carbpol.2020.117232","article-title":"Comprehensive landscape of heparin therapy for COVID-19","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2022.01.019_bib41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.apsb.2022.01.019_bib42","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1055\/a-1347-6070","article-title":"Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study","volume":"121","author":"Di Castelnuovo","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.apsb.2022.01.019_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2022.01.019_bib44","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/acs.nanolett.0c02278","article-title":"Cellular nanosponges inhibit SARS-CoV-2 infectivity","volume":"20","author":"Zhang","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2022.01.019_bib45","article-title":"Inhalable nanocatchers for SARS-CoV-2 inhibition","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.019_bib46","doi-asserted-by":"crossref","first-page":"27141","DOI":"10.1073\/pnas.2014352117","article-title":"Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines","volume":"117","author":"Rao","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.019_bib47","article-title":"Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin","author":"Zeng","year":"2021","journal-title":"Glycoconj J"},{"key":"10.1016\/j.apsb.2022.01.019_bib48","article-title":"Simulation of the omicron variant of SARS-CoV-2 shows broad antibody escape, weakened ACE2 binding, and modest increase in furin binding","author":"Jawaid","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2022.01.019_bib49","article-title":"Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry","author":"Kastenhuber","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2022.01.019_bib50","doi-asserted-by":"crossref","first-page":"100774","DOI":"10.1016\/j.eclinm.2021.100774","article-title":"Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients","volume":"33","author":"Pawlowski","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.apsb.2022.01.019_bib51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3389\/fphar.2020.01307","article-title":"The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review","volume":"11","author":"Gozzo","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:52:16Z","timestamp":1761929536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2211383522000491"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}